Combination therapy has been a norm in clinical practice to effectively treat cancer. Besides polytherapy, nowadays, smart and nanobased drug carriers are extensively being explored to deliver drugs according to pathophysiological environment of diseases. In this regard, herein we designed intelligent mesoporous architecture, incorporating both combinational therapy with smart nanotechnology, to simultaneously deliver two highly hydrophobic chemotherapeutic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 2 drugs in response to extracellular and/or intracellular acidic environ of tumor. Novelty of the system lies in the employment of acid responsive ZnO QDs to clog not only the nanochannels of mesoporous silica, encapsulating one hydrophobic drug, but also exploitation of chelate forming propensity of another hydrophobic drug (curcumin) to load a significant quantity onto the surface of ZnO nanolids. Cell viability results revealed an extraordinarily high cytotoxic efficiency of that lethal drug cocktail even at a concentration as low as 3 μg/mL nanocarrier. We envision that this sophisticated nanocarrier, which utilizes both interior pore and exterior surface of nanolids for loading different hydrophobic guest molecules and their subsequent acid responsive release, will undoubtedly, illustrates its remarkable potential in targeted chemotherapy.
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INTRODUCTION
Recently, cancer has gained a status as one of the leading health risk in terms of mortality, morbidity and economic costs. Medical community has, in this regard, made great strides to tackle this haunting spectre through addressing the molecular underpinnings responsible for this complex disease. [1] [2] [3] [4] Despite those substantial developments, death rates from cancer have unfortunately not altered over the decades. 5 Chemotherapy has been a standard cancer treatment, which indiscriminately target actively dividing cells throughout the body. This non-targeted onslaught inevitably results in the killing of not only cancer cells, but also healthy ones come under attack. Water solubility and drug resistance poses further terrific challenges for effective cancer therapy. Intensive research efforts have been dedicated towards the development of targeted and smart drug carriers in order to efficiently combat all these obstacles. Luckily, advancement in the nanotechnology in recent times also has proven a great boon for oncology, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   3 owing to well-established passive targeting capability of nanoparticles. [1] [2] [3] [4] [5] [6] With time, plethora of sophisticated nanoparticle-based drug delivery systems has been engineered to ferry cytotoxic drugs or therapeutic genes into malignant cells, without harming healthy cells. Notably, all of those nanoplatforms mostly carry one drug, however in clinical practice; multiple drugs are routinely prescribed to effectively treat cancer. The driving force for the clinical preference and established high efficacy of combination therapy is actually the development of synergy among the different drugs and prevention of drug resistance, which is considered a leading cause of chemotherapy failure. It should also be kept in mind that the use of multiple drugs is indeed escorted with more life-threatening side effects; thus, there is substantial need to integrate combinational therapy with nanotechnology. Researchers and clinicians are now working
together to design such a nanoarchitecture which are capable of loading multiple cytotoxic drugs, with different solubilities and working mechanism, into a single nanocarrier. 7 Among all the available nanoplatforms, mesoporous silica nanoparticles (MSNs) have been increasingly explored as promising vehicles for intracellular drug delivery, mainly because of their excellent biocompatibility and high surface area. [8] [9] [10] Besides highly porous structure for efficient drug loading, the ease with which we introduce organic moieties onto the surface of MSNs really empowers us to exploit it for variety of other biomedical applications. For instance, mesoporous silica has been widely demonstrated as stimuli responsive drug delivery vehicle to minimize the premature release of cytotoxic drugs by manipulating diverse kinds of gatekeepers.
Varieties of extrinsic and intrinsic triggers have been tried to regulate the release of cargo molecules. [11] [12] [13] However, in relation to chemotherapy, pH responsive nanoparticles are highly necessitated due to the existence of slightly acidic pH value (pH 6.5-7.0) of inflamed tissues, primary tumors, and metastasized tumors, compared with normal tissues (pH 7.4). Aberrant 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 glycolytic metabolism actually contributes to the mildly acidic environment of cancer cells. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5 mesoporous silica nanoparticles are capped with acid sensitive ZnO QDs. Subsequently, another cost-effective multi-purpose drug (curcumin) is additionally loaded onto ZnO nanolids with an objective to achieve acid responsive multidrug delivery in pancreatic cancer cells. ZnO QDs in this study simultaneously acts as nanocaps to block the release of encapsulated drug and provides conjugating site for loading another highly hydrophobic drug via coordinate bond (Scheme 1).
Drug release profile demonstrates an efficient burst-like release behavior of curcumin, whereas,
CPT is released in a controlled fashion but after the dissolution of ZnO nanolids in response to mildly acidic conditions.
EXPERIMENTAL SECTION

Synthesis of Mg Doped ZnO Quantum dots:
ZnO QDs were prepared using a previously reported protocol with a slight modification. Zinc acetate (550 mg, 2.5 mmol) and magnesium acetate (56mg, 0.25 mmol) were dissolved in boiling ethanol (30 mL) under vigorous stirring. In a separate flask, NaOH (120 mg, 3.5 mmol) was dissolved in refluxing ethanol (10 mL). The salt solutions were then cooled down in ice bath. The ethanolic NaOH was later quickly injected into the former flask. The mixture was stirred for 8 hours for particles growth and the resulting transparent quantum dots dispersion displayed an intense green emission, under UV lamp excitation at 365 nm. Finally, ZnO quantum dots were precipitated using hexane as a nonsolvent. 
Synthesis of
Synthesis of Mesoporous
Silica Nanosphere: Following a previously reported procedure, mesoporous silica nanoparticles were synthesized. [6] Firstly, CTAB (1.0 g, 2.7 mmol) was dissolved in 480 mL of nanopure water. Sodium hydroxide aqueous solution (2.00 M, 3.5 mL)
was introduced into the CTAB solution and the temperature of the mixture was increased to 80 °C. After attaining the desired temperature, TEOS (5.0 mL, 22.4 mmol) was added dropwise to the above alkaline surfactant solution under vigorous stirring. The mixture was allowed to stir for 2 h to produce a white precipitate. The resulting solid crude product was filtered, washed with nanopure water and ethanol, dried at 60 °C. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   7 introduced into DMSO solution of camptothecin (5 mL, 1 mg mL −1 ) and stirred for 12 h. Later, the above solution was dispersed in 30 mL of water and further stirred for 6 h. After loading, the solution was centrifuged and washed with PBS. In order to cap the CPT loaded COOH-MSNs, the powder was dispersed in water, and then 15 mg EDC and 5 mL of ZnO-NH 2 aqueous
Synthesis of Carboxylic
solutions ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 (FBS, Tianhang bioreagent Co., Zhejiang) and penicillin/streptomycin (100 U mL −1 and 100 µg mL −1 , respectively,) in a humidified 5% CO 2 atmosphere at 37 °C. 
Cell
Confocal Laser Scanning Microscopy (CLSM):
To check cellular uptake and release of both drugs, BxPC-3 cells were cultured in an 12-well chamber slide with one piece of cover glass at the bottom of each chamber in incubation medium (DMEM) for 24 h. Double drug ZnO@MSNs formulations were added into the incubation medium at the concentration of 50 and 100 µg mL −1 for 4 h incubation in 5% CO 2 at 37 °C. After the medium was removed, the cells were washed twice with PBS (pH = 7.4) and the cover glass was visualized under a laser scanning confocal microscope (FluoView FV1000, Olympus). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Amine functionalized mesoporous silica nanoparticles (MSNs-NH 2 ) were firstly synthesized according to a previously established method. Post grafting strategy was employed to introduce amine moiety for further modification. The surface of MSNs was afterwards modified with carboxylic groups to assist in the blocking of drug loaded nanochannels, using ZnO nanolids.Transmission electron microscopy (TEM) and Scanning electron microscopy UV-Vis absorption spectroscopy was used to evaluate the loading amountof curcumin, which indicated a fairly high dose of drug loading (7.4 %). Since, quinone and phenol moieties exhibits a pronounced affinity towards divalent metal ions, that is why, transition metal (Zn 2+ ) in this study ensured the loading of curcumin via chelation. 22 As mentioned above, mesoporous silica has undoubtedly been reported as hydrophobic drugs carrier, but actually it always carried one 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 drug at a time, it has never been explored for the delivery of two hydrophobic drugs simultaneously in response to environmental conditions. This strategy, for the first time, make sure the delivery of two hydrophobic drugs using mesoporous silica as nanocarrier, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 mildly acidic medium. ICP-OES data (Figure 2b ) also shed some light on the dissolution of ZnO. Wide-angle powder X-ray diffraction (XRD) patterns of ZnO@MSNs similarly provides a convincing proof of the existence and dissolution of ZnO as revealed in Figure 2a .
RESULTS AND DISSCUSSION
Generally, drugs are loaded into nanocarriers by utilizing weak non-covalent interactions, such as, physical adsorption, electrostatic interaction and π-π stacking, and subsequently their release is accomplished by breaking these labile bonds between the host and guests. Metal ion-ligand interactions have scarcely been used to load drugs in nanocarriers. In this study, coordination chemistry was exploited to efficiently load another drug (curcumin) onto ZnO nanolids.
Interaction between divalent transition metal ions and curcumin is clearly visible from the color change of curcumin solutions as illustrated in Figure 3c . The color of CPT loaded MSNs was remarkably altered from off-white to intense orange after curcumin loading, due to the formation of metal complex. Previously, several studies have been reported regarding the complexation of anthracyclines drugs by metal ions, which is mainly attributed to the presence of electron rich acetylacetone, hydroxyl, and even, in some instances, the amino groups. 23-25 Absorption and fluorescence techniques facilitated to validate the interaction between curcumin and metal ions.
After chelation, red shift in the absorption maximum of curcumin from 425 nm to 440 nm was detected, suggesting the deprotonation of hydroxyl and conjugation of quinone groups by the metal ions (Figure 3a) . Likewise, fluorescence quenching of ZnO QDs also indicated its successful loading onto the ZnO surfaces via complexation. Prior to this interaction, both curcumin and ZnO nanolids were luminescent, but coordination-mediated binding of curcumin with ZnO QDs resulted in highly efficient quenching of both species as revealed in Figure 3b and photographs in Figure 3c . Furthermore, the surface modification and loading of drugs were confirmed by Fourier Transform infrared (FTIR) spectroscopy ( Figure S5 ). As far as curcumin 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 loading goes, the band at 1580 cm −1 refers to the stretching vibration of carbonyl groups of curcumin, suggesting the successful loading of curcumin.
To prove the concept of pH responsive release of two drugs, different MSNs formulations were incubated in water and acetate buffers (pH 6.0) to evaluate the released quantities of both drugs, using UV/Visible spectroscopy. Firstly, the release pattern of one drug formulation (CPTZnO@MSNs) was evaluated. At physiological pH, the ZnO nanolids were found to be quite stable and remained intact, consequently, relatively low CPT leakage was observed from the silica nanoreservoir as reveled in Figure 4a . On the contrary, exposure to slightly acidic environ inevitably resulted in a rapid disintegration of ZnO nanolids that in turn opens the mesopores to release entrapped CPT molecules. Lowering the pH to 6.0, mimicking the extracellular tumor environment, triggered a considerable release of CPT. It was found that almost 100 % of the nanolids were suddenly dissolved from the outlets of nanopores, as confirmed earlier, led to complete opening of pores and accordingly CPT molecules started releasing in a controlled fashion. Secondly, release profiles of two drug nanoformulation (CUR-CPT-ZnO@MSNs) was similarly determined at different pH levels. Expectedly, two drug formulations displayed almost negligible release of both drugs, due to the capping of pores and stability of CUR-metal complex at pH 7.0. Only ~15 % of CPT and 3 % curcumin were released after 6 days incubation. Apart from the stability of ZnO at physiological pH, the dative bond between Zn 2+ and curcumin is also quite stable at pH 7.0, as a result, no drug release was observed at neutral pH.
Mechanistically,since chelation is a pH dependent phenomenon, thus, formation and cleavage of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 CPT free ZnO@MSNs formulation was unable to cause any cell damage at such a low dose. This cytotoxicity of CPT containing formulation was consistent with the in vitro drug release data, which suggested a sustained pH sensitive release of CPT from ZnO@MSNs for the sake of comparison, curcumin containing ZnO@MSNs formulation was also tested, which likewise resulted in a significant decrease in cell viability in a concentration-dependent manner, with a (IC 50 ) value of less than ~6 μg/mL drug formulation. Unexpectedly, two drug formulations at low drug concentrations exhibited a slightly less inhibiting capacity against the cell proliferation than either CPT or curcumin alone, possibly due to antagonistic effect, but at higher concentrations all drug formulations proved to be extremely lethal. It is worth mentioning that curcumin was loaded onto the surface of nanocarrier and exhibited a burst-like release behavior, therefore, it presumably works as an antioxidant initially against slowly releasing CPT 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Efficient cell uptake of nanocarriers is inevitably linked with efficacious chemotherapy, therefore, cellular uptake and intracellular release of multiple drugs was evaluated by using 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 advantageous, while considering the acidic cancer micro-environment or acidic cellular compartments of cancer cells.
CONCLUSIONS
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